American gastroenterological association institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease

Gastroenterology

Volumn 145, Issue 6, 2013, Pages

  Dassopoulos, Themistocles ^a   Sultan, Shahnaz ^b   Falck Ytter, Yngve T ^c   Inadomi, John M ^d   Hanauer, Stephen B ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFECTION; LYMPHOMA; MAINTENANCE THERAPY; MEDICAL SOCIETY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84888269838     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.10.046     Document Type: Article

References (70)

1. M.D. Kappelman, C.Q. Porter, and J.A. Galanko Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease Inflamm Bowel Dis 17 2011 62 68
2. M.D. Kappelman, S.L. Rifas-Shiman, and K. Kleinman The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States Clin Gastroenterol Hepatol 5 2007 1424 1429
3. M.D. Kappelman, S.L. Rifas-Shiman, and C.Q. Porter Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults Gastroenterology 135 2008 1907 1913
4. A.F. Peery, E.S. Dellon, and J. Lund Burden of gastrointestinal disease in the United States: 2012 update Gastroenterology 143 2012 1179 1187 e1-3
5. L. Peyrin-Biroulet, E.V. Loftus Jr., and J.F. Colombel Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts Inflamm Bowel Dis 17 2011 471 478
6. L.J. Herrinton, L. Liu, and J.D. Lewis Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002 Am J Gastroenterol 103 2008 1998 2006
7. S.B. Hanauer Inflammatory bowel disease N Engl J Med 334 1996 841 848
8. T. Dassopoulos, J.M. Inadomi, and J.D. Lewis The development of clinical guidelines by the American Gastroenterological Association Gastroenterology 138 2010 417 418
9. S. Sultan, Y. Falck-Ytter, and J.M. Inadomi The AGA institute process for developing clinical practice guidelines part one: grading the evidence Clin Gastroenterol Hepatol 11 2013 329 332
10. J.P. Terdiman, C. Gruss, and J.J. Heidelbaugh American Gastroenterological Association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease Gastroenterology 145 2013 1459 1463
11. G.R. Lichtenstein, B.G. Feagan, and R.D. Cohen Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry Am J Gastroenterol 107 2012 1409 1422
12. G.R. Lichtenstein, B.G. Feagan, and R.D. Cohen Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry Clin Gastroenterol Hepatol 4 2006 621 630
13. B.J. Shea, J.M. Grimshaw, and G.A. Wells Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews BMC Med Res Methodol 7 2007 10
14. Review Manager (RevMan) (computer program). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
15. G.A. S.B. Wells, and D. O'Connell The Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses 2011 Ottawa Hospital Research Institute Ottawa, Ontario, Canada www.ohri.ca/programs/ clinical-epidemiology/oxford.htm Accessed November 14, 2012
16. S. Candy, J. Wright, and M. Gerber A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
17. K. Ewe, A.G. Press, and C.C. Singe Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 105 1993 367 372
18. R. Oren, M. Moshkowitz, and S. Odes Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial Am J Gastroenterol 92 1997 2203 2209
19. R.W. Summers, D.M. Switz, and J.T. Sessions Jr. National Cooperative Crohn's Disease Study: results of drug treatment Gastroenterology 77 1979 847 869
20. W. Reinisch, J. Panes, and M. Lemann A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease Am J Gastroenterol 103 2008 2284 2292
21. K.J. Khan, M.C. Dubinsky, and A.C. Ford Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis Am J Gastroenterol 106 2011 630 642
22. J.W. Singleton, D.H. Law, and M.L. Kelley Jr. National Cooperative Crohn's Disease Study: adverse reactions to study drugs Gastroenterology 77 1979 870 882
23. B.G. Feagan, J. Rochon, and R.N. Fedorak Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
24. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
25. M. Lemann, J.Y. Mary, and B. Duclos Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 2006 1054 1061
26. S.R. Targan, S.B. Hanauer, and S.J. van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029 1035
27. S.B. Hanauer, W.J. Sandborn, and P. Rutgeerts Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2006 323 333 quiz 591
28. W.J. Sandborn, P. Rutgeerts, and R. Enns Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 146 2007 829 838
29. M. Watanabe, T. Hibi, and K.G. Lomax Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease J Crohns Colitis 6 2012 160 173
30. W.J. Sandborn, B.G. Feagan, and S. Stoinov Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238
31. W.J. Sandborn, S. Schreiber, and B.G. Feagan Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial Clin Gastroenterol Hepatol 9 2011 670 678 e3
32. S. Schreiber, P. Rutgeerts, and R.N. Fedorak A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 2005 807 818
33. T.A. Winter, J. Wright, and S. Ghosh Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study Aliment Pharmacol Ther 20 2004 1337 1346
34. A.C. Ford, W.J. Sandborn, and K.J. Khan Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 644 659 quiz 660
35. J. Mate-Jimenez, C. Hermida, and J. Cantero-Perona 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease Eur J Gastroenterol Hepatol 12 2000 1227 1233
36. S. Ardizzone, S. Bollani, and G. Manzionna Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study Dig Liver Dis 35 2003 619 627
37. A.A. Alfadhli, J.W. McDonald, and B.G. Feagan Methotrexate for induction of remission in refractory Crohn's disease Cochrane Database Syst Rev 2005 CD003459
38. M. Lemann, J.Y. Mary, and J.F. Colombel A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine Gastroenterology 128 2005 1812 1818
39. D.P. O'Donoghue, A.M. Dawson, and J. Powell-Tuck Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease Lancet 2 1978 955 957
40. M. Vilien, J.F. Dahlerup, and L.K. Munck Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year Aliment Pharmacol Ther 19 2004 1147 1152
41. L. Beaugerie, N. Brousse, and A.M. Bouvier Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 2009 1617 1625
42. L.J. Herrinton, L. Liu, and X. Weng Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease Am J Gastroenterol 106 2011 2146 2153
43. B.G. Feagan, R.N. Fedorak, and E.J. Irvine A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
44. V. Patel, J.K. Macdonald, and J.W. McDonald Methotrexate for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 2009 CD006884
45. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
46. P. Rutgeerts, G. D'Haens, and S. Targan Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
47. J.F. Colombel, W.J. Sandborn, and P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65
48. W.J. Sandborn, S.B. Hanauer, and P. Rutgeerts Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239
49. S. Schreiber, M. Khaliq-Kareemi, and I.C. Lawrance Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 2007 239 250
50. G. Van Assche, C. Magdelaine-Beuzelin, and G. D'Haens Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial Gastroenterology 134 2008 1861 1868
51. G.R. Lichtenstein, S.B. Hanauer, and W.J. Sandborn Management of Crohn's disease in adults Am J Gastroenterol 104 2009 465 483 quiz 464, 484
52. C. Mowat, A. Cole, and A. Windsor Guidelines for the management of inflammatory bowel disease in adults Gut 60 2011 571 607
53. A. Dignass, G. Van Assche, and J.O. Lindsay The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 2010 28 62
54. T. Bourne, G. Fossati, and A. Nesbitt A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action BioDrugs 22 2008 331 337
55. D. Tracey, L. Klareskog, and E.H. Sasso Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
56. A. Nesbitt, G. Fossati, and M. Bergin Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm Bowel Dis 13 2007 1323 1332
57. G.R. D'Haens, R. Panaccione, and P.D. Higgins The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106 2011 199 212 quiz 213
58. E. Prefontaine, J.K. Macdonald, and L.R. Sutherland Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Cochrane Database Syst Rev 2009 CD000545
59. J.A. Singh, G.A. Wells, and R. Christensen Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2011 CD008794
60. K.J. Aaltonen, L.M. Virkki, and A. Malmivaara Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis PLoS One 7 2012 e30275
61. H. Sokol, and L. Beaugerie Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle Gut 58 2009 1427 1436
62. A. Kandiel, A.G. Fraser, and B.I. Korelitz Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 54 2005 1121 1125
63. A.C. Vos, N. Bakkal, and R.C. Minnee Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study Inflamm Bowel Dis 17 2011 1837 1845
64. G.R. Burmester, R. Panaccione, and K.B. Gordon Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Ann Rheum Dis 72 2013 517 524
65. M.A. Lopez-Olivo, J.H. Tayar, and J.A. Martinez-Lopez Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis JAMA 308 2012 898 908
66. G. Moulis, A. Sommet, and J. Bene Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses PLoS One 7 2012 e48991
67. X. Mariette, D. Cazals-Hatem, and J. Warszawki Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France Blood 99 2002 3909 3915
68. C.A. Siegel, S.R. Finlayson, and B.E. Sands Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model Clin Gastroenterol Hepatol 10 2012 46 51
69. J.P. Gisbert, and J. Panes Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review Am J Gastroenterol 104 2009 760 767
70. V. Billioud, W.J. Sandborn, and L. Peyrin-Biroulet Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review Am J Gastroenterol 106 2011 674 684